Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT03461237
Recruiting Observational

Chinese Second Hip Fracture Evaluation

NCT03461237 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Jishuitan Hospital
Phase
Observational
Started
2017-05-01
Last updated
2025-08-17

Condition(s) studied

Hip FracturesOsteoporosis

Study summary

1. To Compare overall rates of second hip fractures in both genders,
2. To determine the effect of hip fracture on proximal femoral volumetric bone mineral density (vBMD), bone structure and muscle by quantitative computed tomography(QCT),
3. To evaluate the contribution of QCT-image analysis to the prediction of the second hip fracture risk.
4. To identify the differences between femoral neck fracture and trochanter fracture following hip fracture

Eligibility

Sex
ALL
Min age
50 Years
Max age
95 Years
Healthy volunteers
Accepted
Inclusion Criteria: * a:Osteoporotic patients b:Osteoporotic hip fracture patients (femoral neck fracture and femoral trochanteric fracture) c: Be willing to and be able to join in the study and sighed the informed consent Exclusion Criteria: * a:Under 47years old b:Non-surgical repair of hip fracture c:Pathologic fracture d:Violence-related trauma e:Bilateral hip implants or have hip replacement on the non-fractured side

Primary outcome measure(s)

  • Hip re-fracture — 3 years
    The incidence and location of second hip fracture
  • all cause death — 2 year
    all cause death

Trial sites (1)

FacilityCityRegionStatus
Beijing ji shui tan hospital Beijing Beijing Municipality Recruiting

More Beijing Jishuitan Hospital trials in China

The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures Recruiting
Robot-Assisted Closed Reduction and Internal Fixation for Distal Femoral Fractures Recruiting
A RCT of Collagen Scaffold for the Repair of Talus Cartilage Injury Enrolling by invitation
Robot-Assisted Closed Reduction and Internal Fixation for Extra-Articular Distal Tibial Fractures Recruiting
Does Medial Raw Anchor Necessary During Tendon Repair Combined With Microfracture Enrolling by invitation

Other trials for the same condition

Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging Recruiting
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture Active, not recruiting
Epidemiological Study of Osteoporosis in the Elderly Population of Shandong Province Recruiting
Robot Assisted Minimally Invasive Treatment Versus Conventional Surgery for FFP3-4 Fragility Fractures of the Pelvis in Elderly Patients Starting soon
Spinal Versus General Anesthesia on Postoperative Pulmonary Complications Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03461237 on ClinicalTrials.gov ↗ ← All trials in China